FibroGen (FGEN) Scheduled to Post Earnings on Monday

FibroGen (NASDAQ:FGEN) will post its quarterly earnings results after the market closes on Monday, May 6th. Analysts expect FibroGen to post earnings of ($0.31) per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.15). The firm had revenue of $27.14 million during the quarter, compared to analysts’ expectations of $40.00 million. On average, analysts expect FibroGen to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

FibroGen Stock Performance

Shares of NASDAQ FGEN opened at $1.14 on Friday. The business’s 50 day moving average price is $1.73 and its 200-day moving average price is $1.22. FibroGen has a fifty-two week low of $0.33 and a fifty-two week high of $19.47. The company has a market cap of $113.40 million, a price-to-earnings ratio of -0.39 and a beta of 0.88.

Wall Street Analyst Weigh In

Separately, William Blair reiterated a “market perform” rating on shares of FibroGen in a report on Tuesday, February 27th. One analyst has rated the stock with a sell rating and four have issued a hold rating to the company. According to data from MarketBeat, FibroGen has a consensus rating of “Hold” and an average price target of $17.00.

Insider Buying and Selling

In other news, CEO Thane Wettig acquired 50,000 shares of the company’s stock in a transaction that occurred on Thursday, March 7th. The shares were bought at an average price of $1.91 per share, with a total value of $95,500.00. Following the completion of the purchase, the chief executive officer now directly owns 470,178 shares in the company, valued at $898,039.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.39% of the stock is owned by insiders.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.